FY2027 EPS Estimates for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Increased by Wedbush

Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREFree Report) – Research analysts at Wedbush lifted their FY2027 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a report released on Monday, January 29th. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings of $0.98 per share for the year, up from their prior estimate of $0.94. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($8.47) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s FY2028 earnings at $1.63 EPS.

Other analysts also recently issued reports about the company. Wells Fargo & Company initiated coverage on Ultragenyx Pharmaceutical in a research report on Friday, December 8th. They issued an “overweight” rating and a $72.00 price objective on the stock. Morgan Stanley dropped their target price on Ultragenyx Pharmaceutical from $90.00 to $84.00 and set an “overweight” rating for the company in a research note on Friday, November 3rd. Robert W. Baird upped their target price on Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an “outperform” rating in a research note on Tuesday. StockNews.com upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Friday, December 8th. Finally, Piper Sandler dropped their target price on Ultragenyx Pharmaceutical from $135.00 to $130.00 and set an “overweight” rating for the company in a research note on Wednesday, October 25th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $90.60.

View Our Latest Report on Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ:RARE opened at $44.88 on Wednesday. Ultragenyx Pharmaceutical has a 52-week low of $31.52 and a 52-week high of $54.98. The stock’s fifty day simple moving average is $44.42 and its 200-day simple moving average is $39.92.

Ultragenyx Pharmaceutical (NASDAQ:RAREGet Free Report) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($2.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.08) by ($0.15). Ultragenyx Pharmaceutical had a negative net margin of 154.87% and a negative return on equity of 346.33%. The company had revenue of $98.05 million during the quarter, compared to analysts’ expectations of $99.38 million.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sands Capital Management LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at about $123,335,000. Norges Bank acquired a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at about $33,526,000. BlackRock Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 12.4% in the first quarter. BlackRock Inc. now owns 4,873,356 shares of the biopharmaceutical company’s stock valued at $195,422,000 after buying an additional 536,513 shares in the last quarter. State Street Corp grew its stake in shares of Ultragenyx Pharmaceutical by 26.1% in the second quarter. State Street Corp now owns 2,457,308 shares of the biopharmaceutical company’s stock valued at $146,603,000 after buying an additional 508,624 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Ultragenyx Pharmaceutical by 17.1% in the first quarter. Wellington Management Group LLP now owns 3,370,245 shares of the biopharmaceutical company’s stock valued at $244,747,000 after buying an additional 492,842 shares in the last quarter. 96.37% of the stock is currently owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

(Get Free Report)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Read More

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.